Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5(a) - Pfizer Inc.

2 Nov 2015 11:37

RNS Number : 1981E
J.P. Morgan Securities LLC
02 November 2015
Β 

Ap24

Β 

FORMΒ 38.5(a)

Β 

IRISHΒ TAKEOVERΒ PANEL

Β 

DISCLOSUREΒ UNDERΒ RULEΒ 38.5(a)Β OFΒ THEΒ IRISHΒ TAKEOVERΒ PANEL ACT,Β 1997,Β TAKEOVERΒ RULES,Β 2013

Β 

DEALINGSΒ BYΒ CONNECTEDΒ EXEMPTΒ PRINCIPALΒ TRADERSΒ WITHΒ RECOGNISEDΒ INTERMEDIARYΒ STATUSΒ ANDΒ DEALINGΒ INΒ AΒ CLIENT-SERVINGΒ CAPACITY

Β 

1. KEYΒ INFORMATION

Β 

Name of exempt principal trader

J.P. Morgan Securities plc

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

30 October 2015

Β 

2. DEALINGSΒ (NoteΒ 2)

Β 

(a) PurchasesΒ andΒ sales

Β 

Total number of relevant secuities acquired

Highest price paid (EUR)(Note 3)

Lowest price paid (EUR)

(Note 3)

Β 

Β 

Total number of securities disposed

Highest price received (EUR) (Note 3)

Lowest price received (EUR)

(Note 3)

804

31.0950

31.0900

Β 

Β 

(b) DerivativesΒ transactionsΒ (otherΒ thanΒ optionsΒ transactions)

Β 

Product name,

e.g. CFD

Nature of transaction

(Note 4)

Number of relevant securities

(Note 5)

Price per unit

(Note 3)

Equity Swap

Long

Β 

804

31.0886

Ap25

Β 

(c) OptionsΒ transactionsΒ inΒ respectΒ ofΒ existingΒ relevantΒ securities

Β 

Β 

(i) Writing,Β selling,Β purchasingΒ orΒ varying

Β 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

Β 

Β 

(ii) Exercising

Β 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 3)

Β 

Β 

3. Β OTHERΒ INFORMATION

Β 

Agreements,Β arrangementsΒ orΒ understandingsΒ relatingΒ toΒ optionsΒ orΒ derivatives

Β 

FullΒ detailsΒ ofΒ anyΒ agreement,Β arrangementΒ orΒ understandingΒ betweenΒ theΒ person disclosingΒ andΒ anyΒ otherΒ personΒ relatingΒ toΒ theΒ votingΒ rightsΒ ofΒ anyΒ relevantΒ securities

underΒ anyΒ optionΒ referredΒ toΒ onΒ thisΒ formΒ orΒ relatingΒ toΒ theΒ votingΒ rightsΒ orΒ futureΒ acquisition

orΒ disposalΒ ofΒ anyΒ relevantΒ securitiesΒ toΒ whichΒ anyΒ derivative referredΒ toΒ onΒ thisΒ formΒ is

referenced.Β IfΒ none,Β thisΒ shouldΒ beΒ stated.

Β 

Β 

Β 

Β 

Β 

Β 

Date of disclosure

02 November 2015

Contact name

Tung Le

Β 

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan Plc

Nature of connection (Note 6)

Adviser to Allergan Plc

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
ISEFSMFFEFISEDF
Date   Source Headline
16th May 201411:29 amRNSForm 8.5 (EPT/RI)
16th May 201411:27 amRNSForm 8 (DD) - [Pfizer Inc]
16th May 201411:18 amRNSForm 8.3 - Pfizer Inc
16th May 201411:13 amRNSForm 8.5 (EPT/RI)
16th May 201411:12 amRNSForm 8.5 (EPT/NON-RI)
16th May 201411:00 amRNSRule 2.10 Announcement
16th May 201410:31 amRNSForm 8.3 - Pfizer Inc
16th May 20149:18 amRNSRule 2.10 Announcement
16th May 20147:00 amPRNForm 8.3 - Pfizer Inc.
15th May 20145:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20145:50 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20145:16 pmRNSForm 8 (DD) - [Pfizer Inc]
15th May 20145:14 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
15th May 20143:52 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:50 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:33 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:32 pmRNSForm 8.3 - [Pfizer/Astrazeneca]
15th May 20143:28 pmBUSForm 8.3 - Pfizer Inc
15th May 20143:26 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
15th May 20143:22 pmRNSForm 8.3 - Pfizer Inc
15th May 20143:10 pmRNSForm 8.5 (EPT/NON-RI) Amendment
15th May 20143:02 pmBUSForm 8.3 - Pfizer Inc.
15th May 20142:50 pmRNSForm 8.3 - [PFIZER INC]
15th May 20142:42 pmBUSForm 8.3 - Pfizer Inc
15th May 20142:29 pmRNSForm 8.3 - [Pfizer Inc]
15th May 20141:55 pmRNSForm 8.5 (EPT/RI) Pfizer Inc. Amendment
15th May 20141:36 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:34 pmRNSForm 8.3 - AstraZeneca Plc
15th May 20141:26 pmRNSForm 8.3 - Pfizer Inc
15th May 20141:24 pmRNSForm 8 (DD) - Pfizer Inc.
15th May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
15th May 201412:57 pmBUSForm 8.3 - Pfizer Inc.
15th May 201412:39 pmRNSForm 8.3 - [AstraZeneca Plc]
15th May 201412:22 pmRNSForm 8.3 - [Pfizer Inc]
15th May 201412:15 pmRNSForm 8.5 (EPT/NON-RI)
15th May 201412:10 pmRNSForm 8.5 (EPT/RI)
15th May 201412:09 pmBUSForm 8.3 - Pfizer Inc
15th May 201411:55 amRNSForm 8.3 - Pfizer, Inc.
15th May 201411:34 amRNSForm 8 (DD) - [Pfizer Inc]
15th May 201411:32 amRNSForm 8.5 (EPT/RI)
15th May 201411:27 amRNSForm 8.5 (EPT/RI) Pfizer Inc
15th May 201411:04 amRNSForm 8.3 - Pfizer Inc
15th May 201411:00 amRNSForm 8.5 (EPT/RI) - Pfizer
15th May 201411:00 amRNSRule 2.10 Announcement
15th May 20149:39 amRNSRule 2.10 Announcement
14th May 20144:48 pmRNSForm 8.3 - Replacement - Pfizer Inc
14th May 20143:31 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc.
14th May 20143:26 pmRNSForm 8.3 - Pfizer Inc
14th May 20143:23 pmRNSForm 8.3 - AstraZeneca Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.